logo_web
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet
✕
  • Clinical Trials
    • Management of medication
    • Management of reimbursement of expenses to patients
    • Supply of medical devices
    • Destruction
    • Calibration of medical devices
    • Import and labeling of medication
    • Masking. Placebos manufacturing
  • Blog
  • Quality
    • Certifications
    • RSE
  • Clients
  • Patient Reimbursement Forms
    • Validation / Expense Reimbursement Sheet

Exceptional measures for tests for problems derived from the emergency by COVID-19

Source: www.actasanitaria.com

The Spanish Agency of Medicines and Health Products (AEMPS), as the competent national authority in the authorization of clinical trials, has proposed a series of recommendations of exceptional application during the period of the COVID-19 crisis in Spain, which are intended to preserve the trial activities as far as possible, guaranteeing the healthcare of the patients, protecting their safety and well-being and preserving the traceability of the actions implemented in this health emergency situation.

“It is essential to maintain the maximum capacity of the health system reducing the risk of infection for the population,” stresses this regulatory body. In addition, he adds that “we must take into account the measures applied in the different autonomous communities after the declaration of the State of Alert by the Government.”

In this context, the AEMPS points out that “scheduled follow-up visits, access by external personnel to the centers and monitoring of the on-site trial could be compromised.” In some cases, he clarifies that “it might be necessary to transfer a patient from one center to another to facilitate their healthcare.” On the other hand, he remarks that “there may be a decrease in the staff of the promoter in charge of monitoring the trial.”

Epidemiological evolution
Likewise, this Agency highlights that “it is important that the promoter, together with the researcher, make a risk analysis and prioritize the activities that are critical and the way in which they should be carried out. Both should evaluate the application of these measures in a proportionate way for each clinical trial considering their particularities, the organization of each center and the epidemiological characteristics of COVID-19 in it ”. These measures may be updated to adapt to epidemiological developments as determined by the Ministry of Health.

Any such exceptional measures taken must be duly documented in the trial file. However, its application does not require prior approval on a case-by-case basis as a substantial modification by the AEMPS or by the Ethics Committee for Drug Research (CEIm), nor the individual notification of serious breaches of the protocol, except when expressly required in the point 2. In the four months following the date in which it is considered that the COVID-19 crisis ended in Spain, the promoter must communicate for each trial a report on the exceptional measures adopted that will be sent to the Agency and the CEIm.

 

At Distefar we support and share exceptional application measures for clinical trials during the period of the COVID-19 crisis in Spain.

Related entries

2 October, 2023

Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research


Leer más
26 September, 2023

More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society


Leer más
19 September, 2023

The pharmaceutical industry’s plan to expand clinical trials in primary care


Leer más

Recent Posts

  • Decentralisation of trials, networking and digitisation, proposals to improve patient participation in clinical research
  • More than 120 molecules in Alzheimer’s research, the great hope for patients, families and society
  • The pharmaceutical industry’s plan to expand clinical trials in primary care
  • Health commitment to the pharmaceutical industry’s Strategic Plan to avoid losing 8,000 million euros
  • Improving patient access to innovative medicines and boosting R&D and manufacturing in Spain are the main priorities of the pharmaceutical industry

Contacta con nosotros


Tfno: +34 955.77.67.67
Fax: +34 955.77.65.56
info@distefar.net


Distefar del Sur
Sede Central

Distefar del Sur S.L.
Av. Umbrete, 58,
41110 Bollullos de la Mitación, Sevilla

Sede Madrid

Calle de Zurbano, 45, 28010 Madrid

CENTRAL

Pol. PIBO. Avda. de Gines, 14
+34 955 776 767 /+34 692 454 913
41110 Bollullos de la Mitación (Sevilla)

DELEGACIÓN MADRID

+34 674 575 115
28010 Madrid

Enlaces de interés

  • Aviso Legal
  • Política de privacidad
  • Política de cookies
  • Contacto

© 2023 Distefar del Sur SL. Todos los derechos reservados. agencianodo.com

  • Contact
  • Private Zone
  • Español
  • English

    [recaptcha]

    In accordance with the provisions of Regulation (EU) 2016/679 and Organic Law 3/2018 regarding Data Protection, we inform you that the data you provide in this form will be incorporated into a file owned by DISTEFAR DEL SUR, SL domiciled in the C / Umbrete 58, (Pol. Ind. Pibo), 41110 of Bollullos de la Mitación (Seville), in order to manage your request.

    In this regard, and if you wish to exercise your rights of access, rectification, cancellation, opposition, portability and limitation, please send a written communication to DISTEFAR DEL SUR, SL, to the address indicated above or to info@distefar.com, attaching copy of your National Identity Document or equivalent identification document.

    Basic information about Data Protection

     Epigraph

    Basic information Data Protection

    Responsable

    DISTEFAR DEL SUR, S.L.

    Purpose

    Process your inquiry / request
    Detailed information on Data Protection

    Legitimation

    Consent
    Detailed information on Data Protection

    Recipients

    It is not expected to carry out data communications to third parties, except legal obligation
    Transfers of data to third countries outside the European Union will not be carried out
    Detailed information on Data Protection

    Rights

    You have the right of access, rectification, deletion, portability of your data, as well as limitation or opposition to your treatment, as detailed in Detailed information on Data Protection

    Additional Information

    You can consult the additional and detailed information on data protection by clicking here Detailed information on Data Protection

    All the data requested / The fields marked with * in the form are mandatory, if not filled in DISTEFAR DEL SUR, S.L. will not be able to meet your request.